{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-099221","form_type":"8-K","ticker":"BCYC","cik":"0001761612","company_name":"BICYCLE THERAPEUTICS PLC","filed_at":"2026-08-20T20:05:23+00:00","discovered_at":"2026-08-20T20:06:01.614922+00:00","generated_at":"2026-08-20T20:06:06.634923+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Bicycle Therapeutics director Charles Swanton resigns effective immediately","bullets":["On August 18, 2026, Charles Swanton resigned as Class II director, committee member, and Clinical Advisory Board member.","Resignation effective immediately; cited personal reasons, no disagreement with company operations.","Ticker BCYC; resignation disclosed in Form 8-K filed August 20, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-099221","json":"https://secwatch.observer/filing/0001104659-26-099221.json","markdown":"https://secwatch.observer/filing/0001104659-26-099221.md","text":"https://secwatch.observer/filing/0001104659-26-099221.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1761612/000110465926099221/0001104659-26-099221-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1761612/000110465926099221/tm2623656d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-20T20:06:06.634923+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}